Belgian biotechnology firm Quantoom Biosciences has formed a strategic partnership with India's TechInvention Lifecare Pvt. Ltd. to advance the development and manufacturing of RNA-based vaccines. The collaboration, formalized through a Memorandum of Understanding on March 4, 2025, during the Belgian Economic Mission to India, aims to enhance the accessibility, scalability, and affordability of RNA-based therapeutics.
Comprehensive RNA Development Platform
The partnership centers on Quantoom's RNA N-Force toolbox, a comprehensive platform that streamlines the RNA vaccine development process. TechInvention will utilize three key components of the platform:
- Ncode for sequence design
- Ntensify for RNA production
- Ncapsulate for bulk lipid-like delivery chemistry encapsulation
The implementation of these tools will be supported by Quantoom's expertise in translational research and regulatory compliance, alongside their established GMP manufacturing capabilities.
Manufacturing Excellence and Global Impact
TechInvention's forthcoming facility in Mumbai, the Global Collaborative Centre for Medical Countermeasures (GCMC), will house end-to-end mRNA production capabilities compliant with EU-GMP standards. The company has set an ambitious target to achieve GMP-ready status for Ntensify midi scale production by the end of 2025.
"This partnership represents a transformative milestone in India's biotechnology landscape," stated Quantoom's representatives, emphasizing the significance of establishing comprehensive mRNA production capabilities in India.
Sustainable Technology and Broader Applications
The collaboration extends beyond human health applications, encompassing animal and environmental health initiatives. The partnership emphasizes environmentally conscious technology, featuring modular, low-carbon-footprint messenger RNA systems that align with global decarbonization efforts.
José Castillo, CEO of Quantoom Biosciences, highlighted the company's mission: "Our technology will, by design, make RNA products accessible and scalable globally. Partnering with TechInvention in India is a vital step toward achieving this goal, into the most populated country in the world."
Strategic Vision for Global Health
Syed Ahmed, director and CEO of TechInvention, emphasized the partnership's broader implications: "This partnership is a significant step toward strengthening India's preparedness for future pandemics while ensuring broader access to RNA-based innovations across low- and middle-income countries."
Expanding Global Partnerships
This collaboration follows Quantoom's recent strategic moves in the RNA therapeutics space. In February 2025, the company announced a separate partnership with EVA Pharma and DNA Script to develop the first digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines for both human and animal health applications.
The series of partnerships demonstrates Quantoom's commitment to expanding global access to RNA-based therapeutics while addressing health inequities in underserved populations. These collaborations represent significant steps toward democratizing advanced pharmaceutical technologies and enhancing global health security.
